<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pramipexole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pramipexole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pramipexole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10988" href="/d/html/10988.html" rel="external">see "Pramipexole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F212309"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mirapex ER;</li>
<li>Mirapex [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867994"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Pramipexole;</li>
<li>APO-Pramipexole;</li>
<li>Auro-Pramipexole;</li>
<li>Mirapex;</li>
<li>RATIO-Pramipexole;</li>
<li>SANDOZ Pramipexole</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F212335"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Parkinson Agent, Dopamine Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F212313"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b> Dosage is expressed as pramipexole dihydrochloride monohydrate salt, consistent with US and Canadian labeling; in some other countries, dosing may be expressed as pramipexole base. Pramipexole dihydrochloride monohydrate salt contains ~70% pramipexole base (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22500116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22500116'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afdbcf58-54a4-4f1f-8310-d12811c549e2">Parkinson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease (monotherapy or adjunctive therapy): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i>
<b>Oral: </b>Initial: 0.125 mg 3 times daily; increase gradually (eg, 0.125 mg/dose) every 5 to 7 days based on response and tolerability up to 4.5 mg/day. Usual dose: 1.5 to 4.5 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spindler.2021','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spindler.2021','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i>
<b>Oral: </b>Initial: 0.375 mg once daily; increase by 0.375 mg every 5 to 7 days based on response and tolerability. Usual dose: 1.5 to 4.5 mg once daily; maximum: 4.5 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spindler.2021','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spindler.2021','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Converting from pramipexole immediate release to pramipexole extended release:</i> May initiate extended release the morning after the last immediate release evening dose is taken. The total daily dose should remain the same.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f697f01-66fe-41f3-8c4d-7ff9a727a5e7">Restless legs syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i>
<b>Oral: </b>Initial: 0.125 mg once daily 2 to 3 hours before bedtime. Daily dose may be increased based on response and tolerability to 0.25 mg after 4 to 7 days. Daily dose may then be increased to 0.5 mg after 4 to 7 days. Alternatively, some experts recommend increasing by 0.125 mg every 2 to 3 days based on response and tolerability to lowest effective dose, up to a maximum of 0.75 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27448465','lexi-content-ref-Silber.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27448465','lexi-content-ref-Silber.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If augmentation occurs (worsening symptoms during dopaminergic therapy), dose earlier in the evening, divide into multiple evening doses, increase dose (keeping at or below 0.75 mg/day), or consider switching to alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27448465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27448465'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy</b>: Do not discontinue abruptly; the manufacturer of the IR and ER formulations recommends reducing dose by 0.75 mg/day until daily dose is 0.75 mg, then reducing by 0.375 mg/day thereafter.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991242"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Dosage is expressed as pramipexole dihydrochloride monohydrate salt, consistent with US and Canadian labeling; in some other countries, dosing may be expressed as pramipexole base. Pramipexole dihydrochloride monohydrate salt contains ~70% pramipexole base (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22500116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22500116'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Pramipexole Dose Adjustments in Altered Kidney Function</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="top">
<tr>
<th align="center"></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Parkinson disease</p></th>
<th align="center">
<p style="text-indent:0em;">Restless legs syndrome</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">Immediate release</p></th>
<th align="center">
<p style="text-indent:0em;">Extended release</p></th>
<th align="center">
<p style="text-indent:0em;">Immediate release</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">
<sup>a</sup> Recommendation extrapolated from Miranda 2004, which demonstrated tolerability of doses up to 0.5 mg once daily in hemodialysis patients with restless legs syndrome. Since pramipexole is negligibly dialyzed, patients with CrCl &lt;15 mL/minute may exhibit similar pharmacokinetics/tolerability.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.125 mg 3 times daily; refer to indication-specific adult dosing section for titration recommendations.</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.375 mg once daily; refer to indication-specific adult dosing section for titration recommendations.</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.125 mg once daily 2 to 3 hours before bedtime; refer to indication-specific adult dosing section for titration recommendations.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to 50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.125 mg twice daily; increase gradually (eg, 0.125 mg/dose) every 5 to 7 days based on response and tolerability; maximum: 0.75 mg 3 times daily.</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.375 mg every other day; may increase to 0.375 mg once daily no sooner than 1 week after initiation. If necessary, may increase by 0.375 mg per dose not more frequently than weekly; maximum recommended dose: 2.25 mg once daily.</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.125 mg once daily 2 to 3 hours before bedtime; may increase to 0.25 mg once daily after <b>14 days</b>. May further increase in 0.125 to 0.25 mg/day increments every <b>14 days</b> based on response and tolerability, up to a maximum of 0.75 mg/day.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to &lt;30 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.125 mg once daily; increase gradually (eg, 0.125 mg/dose) every 5 to 7 days based on response and tolerability; maximum: 1.5 mg once daily.</p></td>
<td align="center">
<p style="text-indent:0em;">Use not recommended.</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.125 mg once daily 2 to 3 hours before bedtime; may increase to 0.25 mg once daily after <b>14 days</b>. May further increase in 0.125 to 0.25 mg/day increments every <b>14 days</b> based on response and tolerability, up to a maximum of 0.75 mg/day.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;15 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.125 mg once daily; increase gradually (eg, 0.125 mg/dose) every 5 to 7 days based on response and tolerability; use with caution; maximum: 0.5 mg once daily.<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Use not recommended.</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 0.125 mg once daily 2 to 3 hours before bedtime; may increase to 0.25 mg once daily after <b>14 days</b>. May further increase in 0.125 to 0.25 mg/day increments every <b>14 days</b> based on response and tolerability, up to a <b>maximum of 0.5 mg/day.<sup>a</sup></b></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31008016','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31008016','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Parkinson disease: </b>Dose as for patients with CrCl &lt;15 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Restless legs syndrome: </b>Initial: 0.125 mg once daily 2 to 3 hours before bedtime. Daily dose may be increased based on response and tolerability to 0.25 mg after 14 days. Daily dose may then be increased to 0.5 mg after an additional 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15007148','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15007148','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzed (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Parkinson disease: </b>Dose as for patients with CrCl &lt;15 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Restless legs syndrome: </b>Initial: 0.125 mg once daily 2 to 3 hours before bedtime. Daily dose may be increased based on response and tolerability to 0.25 mg after 14 days. Daily dose may then be increased to 0.5 mg after an additional 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15007148','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15007148','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important. Based on large V<sub>d</sub>, pramipexole is not likely to be significantly dialyzed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> In general, use not recommended (has not been studied) (expert opinion). For patients with Parkinson disease receiving pramipexole prior to initiation of CRRT who continue to experience motor symptoms, continued use of therapy may be considered.<b></b>Dose as for patients with CrCl &lt;15 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b> PIRRT <b>(eg, sustained, low-efficiency diafiltration):</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important. Based on large V<sub>d</sub>, pramipexole is not likely to be significantly dialyzed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> In general, use not recommended (has not been studied) (expert opinion). For patients with Parkinson disease receiving pramipexole prior to initiation of PIRRT who continue to experience motor symptoms, continued use of therapy may be considered.<b></b>Dose as for patients with CrCl &lt;15 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988491"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, no adjustment expected since undergoes minimal hepatic metabolism.</p></div>
<div class="block doe drugH1Div" id="F212314"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56393062"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Augmentation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Augmentation, a worsening of symptoms beyond the level of severity that was experienced when the medication was initiated, has been reported with dopamine agonists such as pramipexole, in patients with restless leg syndrome (RLS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22937989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22937989'])">Ref</a></span>). In addition to severity, the symptoms occur at an earlier time of day compared to pretreatment timing of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26106453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26106453'])">Ref</a></span>). A pooled meta-analysis reported an overall augmentation rate of 5.6% in RLS with treatment (not specifically with pramipexole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26765466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26765466'])">Ref</a></span>). Historically, treatment with levodopa has been associated with the highest rate followed by dopamine agonists, such as pramipexole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26765466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26765466'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and duration-related; not clearly established. Proposed mechanisms include increased dopamine concentrations in the CNS and overstimulation of the dopamine D<sub>1</sub> receptors compared to dopamine D<sub>2</sub> receptors in the spinal cord (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16987735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16987735'])">Ref</a></span>). Iron deficiency may also reduce the function of the dopamine transporter, increasing dopamine concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16987735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16987735'])">Ref</a></span>). In addition, augmentation may also result from dopamine receptor down-regulation, which lowers tolerance to dopaminergic effects in a circadian manner (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33880737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33880737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Delayed; usually after months of treatment (mean duration 8.8 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14725821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14725821'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26765466','lexi-content-ref-16987735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26765466','lexi-content-ref-16987735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28818004','lexi-content-ref-26765466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28818004','lexi-content-ref-26765466'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• More severe RLS prior to treatment (may be related to higher dose use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28818004','lexi-content-ref-14725821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28818004','lexi-content-ref-14725821'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Iron deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28818004','lexi-content-ref-16987735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28818004','lexi-content-ref-16987735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28818004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28818004'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of IR formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26765466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26765466'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Heart failure</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Studies have identified a possible link between <b>heart failure</b> and pramipexole use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363519','lexi-content-ref-22123498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363519','lexi-content-ref-22123498'])">Ref</a></span>). In these studies, the incidence of heart failure was higher in patients taking pramipexole compared to other dopamine agonists used for Parkinson disease or restless leg syndrome (RLS). This suggests that this adverse effect is most likely not a class effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22109939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22109939'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related. In addition to high affinity for the dopamine D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptors, pramipexole is also an alpha-2 adrenergic receptor agonist. It has been proposed by directly activating alpha-2 adrenergic receptors, this agent may reduce adrenergic tone and myocardial contractility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18688211','lexi-content-ref-24587918','lexi-content-ref-8891576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18688211','lexi-content-ref-24587918','lexi-content-ref-8891576'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Not clearly established. One study demonstrated the highest risk within the first 3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22123498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22123498'])">Ref</a></span>) while two studies suggested otherwise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23881697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23881697'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of cardiac disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23881697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23881697'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23881697','lexi-content-ref-22123498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23881697','lexi-content-ref-22123498'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Impulse control disorders</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pramipexole has been associated with <b>impulse control disorders</b>, manifesting as <b>pathological gambling</b>, <b>increased libido</b> (hypersexuality), compulsive or binge buying/eating, and/or other intense urges (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20484726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20484726'])">Ref</a></span>). The prevalence of impulsive control was reported to range from 2.6% to 34.8% in Parkinson disease (PD). A lower prevalence was reported in patients taking dopamine agonists, such as pramipexole, for restless leg syndrome (RLS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>). Rates of clearly pathological behaviors (ie, behaviors affecting social or occupational functioning) as high as 13% have been reported with therapeutic doses of pramipexole (defined as &gt;2 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19339647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19339647'])">Ref</a></span>). Literature suggests that a clear temporal relationship exists between initiation and symptom onset and rapid resolution of symptoms usually occur after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20484726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20484726'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Possibly dose-related; May be due to activation of dopamine receptors (mostly D<sub>3</sub>) involved in both the nigrostriatal and the reward pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Difficult to determine. Most case reports discussed this presentation within months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20484726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20484726'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher affinity for D<sub>3</sub> receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (for PD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family or personal history of psychiatric symptoms (eg, anxiety and depression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870','lexi-content-ref-20484726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870','lexi-content-ref-20484726'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of impulse control disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700703']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700703'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Earlier onset of PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700703']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700703'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nausea and vomiting</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea </b>and <b>vomiting</b> are known side effects of dopamine agonists, such as pramipexole. Studies have shown no apparent difference between immediate-release and extended-release treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30142750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30142750'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; may be related to direct D<sub>2</sub> receptor agonism within the chemoreceptor trigger zone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29383607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29383607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Commonly seen in early phase of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17578485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17578485'])">Ref</a></span>). It is important to note that reports of nausea and vomiting in studies may be subject to recall bias; so, it is unclear whether the onset of symptoms occurred with the first doses or required weeks of therapy prior to onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29383607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29383607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (possible):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26844792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26844792'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid up-titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26844792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26844792'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Administration on an empty stomach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9578193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9578193'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pramipexole may cause <b>orthostatic hypotension </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30591018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30591018'])">Ref</a></span>). Patients with Parkinson disease (PD) may have an impaired capacity to respond to a postural change due to neurodegenerative processes in the brain stem. Orthostatic hypotension may be asymptomatic or symptomatic, leading to <b>dizziness </b>and <b>falling</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11030798'])">Ref</a></span>). In one systematic review, the risk of hypotension was approximately four times lower with pramipexole than ropinirole when each drug was individually compared with placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12688834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12688834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Primarily by venous and arterial dilation through inhibition of the sympathetic nervous system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11030798'])">Ref</a></span>). Agents with lower affinity for D<sub>2</sub> receptors may be associated with lower risk of orthostatic hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30591018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30591018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur at any point during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11030798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Initiation of therapy or dose escalation</p>
<p style="text-indent:-2em;margin-left:6em;">• Autonomic dysfunction (as with PD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that may cause orthostatic hypotension (eg, antihypertensive or antiarrhythmic medications, diuretics, levodopa, monoamine oxidase inhibitors, tricyclic antidepressants) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212','lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212','lexi-content-ref-11030798'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease (eg, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypovolemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212','lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212','lexi-content-ref-11030798'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients with asthenic features (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychotic-like effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pramipexole may cause or exacerbate behavioral changes, including <b>psychotic symptoms</b> (eg, <b>paranoid ideation</b>, <b>hallucinations</b>, <b>delusions</b>, <b>confusion</b>, <b>mania,</b>
<b>disorientation</b>, <b>aggressive behavior</b>, <b>agitation</b>, <b>delirium</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12688834','lexi-content-ref-16513886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12688834','lexi-content-ref-16513886'])">Ref</a></span>). Data have suggested a higher incidence with pramipexole versus ropinirole when compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12688834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12688834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and duration-related; Pramipexole is a non-ergot full agonist at D<sub>2 </sub>receptors, with some activity at D<sub>3</sub> and D<sub>4</sub> receptors as well (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10223406','lexi-content-ref-7664822']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10223406','lexi-content-ref-7664822'])">Ref</a></span>). Psychosis is thought to result from D<sub>2</sub> receptor stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18728740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18728740'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; one case report identified effects (eg, visual hallucinations) within approximately 2 to 4 weeks of dose up-titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18412854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18412854'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28547577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28547577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28547577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28547577'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid cognitive impairment or dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19515253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19515253'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (hallucinations)</p>
<p style="text-indent:-2em;margin-left:6em;">• Number of comorbidities and concurrent medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19515253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19515253'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Somnolence and sleep attacks</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Somnolence (<b>drowsiness</b>) is an adverse reaction of dopamine agonists, including pramipexole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11798367'])">Ref</a></span>). Patients taking pramipexole may experience sleep attacks (<b>sudden onset of sleep)</b>, defined as sudden, irresistible, overwhelming sleepiness without awareness of falling sleep (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10371546','lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10371546','lexi-content-ref-11798367'])">Ref</a></span>). Sleep attacks may also occur in patients with Parkinson disease (PD) in the absence of dopaminergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Likely multifactorial; related to modulation of dopamine receptors, specifically D<sub>3</sub> agonist activity. May also be the result of increased dopamine, leading to down regulation of dopaminergic input to the reticular activating system. Genetic polymorphisms in dopamine receptors may play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; some cases have occurred more than a year after initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer treatment duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11798367'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11798367'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression in patients with PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11798367'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Disease duration &lt;7 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363881'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &lt;70 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363881'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of sleep disorders (other than RLS)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent alcohol or medications that may cause sedation or increase pramipexole plasma levels</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dopamine agonist <b>withdrawal syndrome</b> (DAWS) has been defined as a stereotyped cluster of physical and psychological symptoms that may be mild, moderate, or severe. Psychiatric symptoms may include <b>anxiety,</b> panic attacks, <b>depression</b>, irritability, <b>agitation,</b> dysphoria, agoraphobia, <b>insomnia,</b> drug cravings, and <b>pain</b>. Physical symptoms may include <b>diaphoresis</b>, flushing, <b>nausea</b>, <b>fatigue</b>, <b>orthostatic hypotension</b>, and <b>vomiting.</b> Psychiatric symptoms are the most common and prominent symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30713891','lexi-content-ref-20065130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30713891','lexi-content-ref-20065130'])">Ref</a></span>). DAWS has been reported mainly in Parkinson disease (PD), where it affects about 15% to 19% of patients who taper or discontinue a dopamine agonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28104232'])">Ref</a></span>). Some recent case reports have identified this syndrome in patients with restless leg syndrome (RLS) as well (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24078717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24078717'])">Ref</a></span>). Symptoms may be self-limited or protracted, lasting for months to years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28104232'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Exact mechanism unknown; may be dose-and duration-related. May be due to sudden changes in dopaminergic stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22993451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22993451'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur at any time during taper or after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28104232'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher daily doses (≥1.5 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20065130','lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20065130','lexi-content-ref-28104232'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cumulative exposure to dopamine agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20065130','lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20065130','lexi-content-ref-28104232'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of impulse control disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20065130','lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20065130','lexi-content-ref-28104232'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of deep brain stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28104232'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F212282"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling as reported with the immediate-release (IR) and extended-release (ER) formulations. IR data are inclusive of trials in early Parkinson disease (PD) without levodopa and restless legs syndrome (RLS). Extended-release (ER) data are from trials in early PD without levodopa.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:0em;margin-left:4em;">Gastrointestinal: Constipation (IR: PD: 12% to 14%, RLS: 4%; ER: 14%), nausea (IR: PD: 24% to 28%, RLS: 11% to 19%; ER: 22%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 1</a>)</span><span class="table-link" style="display:none;">Nausea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Pramipexole: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">388</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.125 to 0.75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">575</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.25 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">88</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (IR: PD: 12% to 25%; ER: 12%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 2</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (IR: PD: 22% to 33%, RLS: 6%; ER: 36%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 3</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, headache (IR: RLS: 16%), insomnia (IR: PD: 4% to 17%; ER: 4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Pramipexole: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">388</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Pramipexole: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">36%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">388</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.125 to 0.75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">575</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (IR: PD:14%; ER: 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (IR: PD: 5%), orthostatic hypotension (ER: 3%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 4</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension</span>, peripheral edema (IR: PD: 5% to 8%; ER: 5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:center;">
<b>Pramipexole: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (IR: PD: 1%), weight loss (IR: PD: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (IR: PD: 1%; ER: 2%), anorexia (IR: PD: 4%), diarrhea (IR: RLS: 1% to 3%), dyspepsia (IR: PD: 3%; ER: 3%), dysphagia (IR: PD: 2%), increased appetite (IR: PD: 2%; ER: 3%), upper abdominal pain (IR: PD: 4%; ER: 3%), vomiting (IR: PD: 4%; ER: 4%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 5</a>)</span><span class="table-link" style="display:none;">Vomiting</span>, xerostomia (IR: PD: 4%, RLS: 3%; ER: 5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Pramipexole: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (IR: PD: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (IR: RLS: 3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (IR: PD: 2%), akathisia (IR: PD: 2%), amnesia (IR: PD: 4%), balance impairment (ER: 2%), confusion (IR: PD: 4%)<span class="lexi-table-link-container"> (<a aria-label="Confusion table link" class="lexi-table-link" data-table-id="lexi-content-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-confusion')">table 6</a>)</span><span class="table-link" style="display:none;">Confusion</span>, depression (ER: 2%), dystonia (IR: PD: 2%), falling (IR: PD: 4%; ER: 4%)<span class="lexi-table-link-container"> (<a aria-label="Falling table link" class="lexi-table-link" data-table-id="lexi-content-falling" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-falling')">table 7</a>)</span><span class="table-link" style="display:none;">Falling</span>, fatigue (IR: PD: 6%, RLS: 9%; ER: 6%), hallucination (IR: PD: 6% to 9%, RLS: &lt;1%; ER: 5%; includes auditory hallucination, visual hallucination, and mixed hallucinations)<span class="lexi-table-link-container"> (<a aria-label="Hallucination table link" class="lexi-table-link" data-table-id="lexi-content-hallucination" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hallucination')">table 8</a>)</span><span class="table-link" style="display:none;">Hallucination</span>, hypoesthesia (IR: PD: 3%), malaise (IR: PD: 2%), myoclonus (IR: PD: 1%), sleep disorder (IR: PD: 3%; ER: 2%), sudden onset of sleep (IR: PD: 6%; ER: 3%)<span class="lexi-table-link-container"> (<a aria-label="Sudden Onset of Sleep table link" class="lexi-table-link" data-table-id="lexi-content-sudden-onset-of-sleep" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sudden-onset-of-sleep')">table 9</a>)</span><span class="table-link" style="display:none;">Sudden Onset of Sleep</span>, vertigo (IR: PD: 2%; ER: 4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Confusion" frame="border" id="lexi-content-confusion" rules="all">
<caption style="text-align:center;">
<b>Pramipexole: Adverse Reaction: Confusion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">388</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Falling" frame="border" id="lexi-content-falling" rules="all">
<caption style="text-align:center;">
<b>Pramipexole: Adverse Reaction: Falling</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hallucination" frame="border" id="lexi-content-hallucination" rules="all">
<caption style="text-align:center;">
<b>Pramipexole: Adverse Reaction: Hallucination</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">388</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">889</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sudden Onset of Sleep" frame="border" id="lexi-content-sudden-onset-of-sleep" rules="all">
<caption style="text-align:center;">
<b>Pramipexole: Adverse Reaction: Sudden Onset of Sleep</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pramipexole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (IR: RLS: 3%), muscle spasm (ER: 5%), tremor (IR: PD: 3%; ER: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (IR: PD: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (IR: PD: 3%; ER: 3%), nasal congestion (IR: RLS: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (IR: PD: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Restless leg syndrome (IR: augmentation, rebound, or worsening of RLS)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all indications and formulations):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure (Mokhles 2012), syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, pruritus, skin rash (Tashkent 2018), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: SIADH (Tomita 2005), weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abnormal stools (tablet residue; may be associated with worsening of PD symptoms)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Retroperitoneal fibrosis (Antonini 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation, altered mental status, behavioral changes, delirium, delusion, disorientation, impulse control disorder (including binge eating, compulsive shopping, increased libido, mania, pathological gambling) (Kolla 2010), paranoid ideation, psychotic symptoms (Li 2008), withdrawal syndrome (including anxiety, diaphoresis, and pain) (Yu 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Abnormal posture (postural deformities including antercollis, camptocormia [bent spine syndrome] [Kim 2012], and pleurothotonus [Pisa syndrome] [Galati 2014]), rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleuropulmonary fibrosis (Andersohn 2009)</p></div>
<div class="block coi drugH1Div" id="F212294"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to pramipexole or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F212279"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dyskinesias: May cause or exacerbate dyskinesias. Use with caution in patients with preexisting dyskinesias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Postural deformity: Postural deformities, including antecollis, camptocormia (Bent Spine Syndrome) and pleurothotonus (Pisa Syndrome) have been reported following initiation, several months into treatment, or after increasing the dose. Consider dose reduction or treatment discontinuation in patients who develop postural deformity (complications may improve).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Psychotic disorder: Avoid use in patients with a major psychotic disorder; may exacerbate symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dose adjustment may be necessary. ER tablets are not recommended for use in patients with CrCl &lt;30 mL/minute or end-stage renal disease requiring hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• ER tablet: Tablet residue resembling a swollen whole or partial tablet may be visible in the stool after taking the ER formulation. Some patients reported a worsening of their Parkinson disease symptoms when tablet residue was observed.</p></div>
<div class="block foc drugH1Div" id="F212288"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as dihydrochloride monohydrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mirapex: 0.125 mg [DSC], 0.25 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mirapex: 0.5 mg [DSC] [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mirapex: 0.75 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mirapex: 1 mg [DSC] [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mirapex: 1.5 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as dihydrochloride monohydrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mirapex ER: 0.375 mg, 0.75 mg, 1.5 mg [DSC], 2.25 mg, 3 mg, 3.75 mg, 4.5 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg</p></div>
<div class="block geq drugH1Div" id="F212275"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F212296"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Mirapex ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.375 mg (per each): $29.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75 mg (per each): $29.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.25 mg (per each): $29.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $29.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.75 mg (per each): $29.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.5 mg (per each): $29.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Pramipexole Dihydrochloride ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.375 mg (per each): $6.11 - $16.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75 mg (per each): $6.11 - $16.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $16.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.25 mg (per each): $16.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $16.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.75 mg (per each): $17.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.5 mg (per each): $16.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pramipexole Dihydrochloride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $2.95 - $3.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $2.94 - $3.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $2.95 - $3.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75 mg (per each): $2.95 - $3.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $2.95 - $3.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $2.95 - $3.34</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867995"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as dihydrochloride monohydrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mirapex: 0.125 mg, 0.25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 0.5 mg, 1 mg, 1.5 mg</p></div>
<div class="block adm drugH1Div" id="F212291"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Administer with or without food; administer with food to decrease nausea. ER tablets should be swallowed whole and not chewed, crushed, or divided. For restless legs syndrome, administer 2 to 3 hours before bedtime; if augmentation occurs, dose earlier in the day, divide into multiple daily doses, or consider switching to alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27448465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27448465'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block use drugH1Div" id="F212289"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease:</b> Treatment of Parkinson disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome (immediate release only):</b> Treatment of moderate to severe primary restless legs syndrome.</p></div>
<div class="block mst drugH1Div" id="F212341"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Mirapex may be confused with Hiprex, Mifeprex, MiraLax</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299931"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT2</p></div>
<div class="block dri drugH1Div" id="F212283"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Injection): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride (Oral). Amisulpride (Oral) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (First Generation [Typical]): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Specifically, the risk of chorea may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Pramipexole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the sedative effect of Pramipexole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: May enhance the hypotensive effect of Pramipexole. DilTIAZem may increase the serum concentration of Pramipexole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Consider alternatives to this combination when possible. If combined, monitor for increased effects/toxicities of OCT2 substrates and consider OCT2 substrate dose reductions when appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with MATE1/2-K substrates when possible. If combined, monitor for increased MATE1/2-K substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with OCT2 substrates when possible. If combined, monitor for increased OCT2 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foslevodopa: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Kava Kava may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risdiplam: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of risdiplam with MATE substrates if possible. If the combination cannot be avoided, monitor closely for adverse effects. Consider a reduced dose of the MATE substrate according to that substrate's labeling if appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamterene: May enhance the hypotensive effect of Pramipexole. Triamterene may increase the serum concentration of Pramipexole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: May enhance the hypotensive effect of Pramipexole. Verapamil may increase the serum concentration of Pramipexole.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F212306"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food intake does not affect the extent of drug absorption although the time to maximal plasma concentration is delayed when taken with a meal. Management: Administer without regard to meals.</p></div>
<div class="block pri drugH1Div" id="F212297"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to the use of pramipexole for the treatment of Parkinson disease (Benbir 2014; Lamichhane 2014; Mucchiut 2004; Tüfekçioglu 2018) or restless legs syndrome (RLS) (Dostal 2013) in pregnant women is limited. Current guidelines note that the available information is insufficient to make a recommendation for the treatment of RLS in pregnant women (Aurora 2012).</p></div>
<div class="block brc drugH1Div" id="F212298"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pramipexole is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole inhibits prolactin secretion in humans and may potentially inhibit lactation. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F212299"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with or without food. May be taken with food to decrease nausea.</p></div>
<div class="block mop drugH1Div" id="F212286"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate and signs/symptoms of postural hypotension (especially during dose escalation); body weight changes; CNS depression, daytime somnolence or preexisting sleep disorder, mental alertness, fall risk, behavior changes (eg, compulsive behaviors); periodic skin examinations; signs/symptoms of heart failure.</p></div>
<div class="block pha drugH1Div" id="F212278"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pramipexole is a nonergot dopamine agonist with specificity for the D<sub>2</sub> subfamily dopamine receptor, and has also been shown to bind to D<sub>3</sub> and D<sub>4</sub> receptors. By binding to these receptors, it is thought that pramipexole can stimulate dopamine activity on the nerves of the striatum and substantia nigra.</p></div>
<div class="block phk drugH1Div" id="F212293"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 500 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~15%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Negligible (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Immediate release: &gt;90%; Extended release (as compared to immediate release): 100%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 8.5 hours; Elderly: 12 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Immediate release: ~2 hours; Extended release: 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (90% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51219555"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is 75% lower with severe impairment (CrCl ~20 mL/min) and approximately 60% lower with moderate impairment (CrCl ~40 mL/min).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The half-life increases approximately 40% and clearance decreases approximately 30% in patients 65 years and older mostly because of reduced renal function with age.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Clearance is approximately 30% lower in women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F212300"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Sifrol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aroltex | Maxtenk | Mirapex | Neurosomat | Nixol | Noxopran | Nulipar lp | Parfeno | Parmital | Pisa | Pramixar | Proats | Sifrol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Calmolan | Oprymea | Pramipexol +pharma | Pramipexol 1a pharma | Pramipexol actavis | Pramipexol bluefish | Pramipexol csc | Pramipexol G.L. | Pramipexol genericon | Pramipexol ratiopharm | Pramipexol sandoz | Pramipexol stada | Pramisol | Sifrol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo pramipexole | Pramipexole an | Pramipexole hydrochloride | Sifrol | Simipex | Simpral</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Parixol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mirapexin | Oprymea | Pramipexol apotex | Pramipexol eg | Pramipexol sandoz | Pramipexol teva | Pramipexole eg | Pramipexole mylan | Sifrol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Medopexol | Mirapexin | Peximyr | Pramicon | Pramipexole | Pramipexole sandoz | Pramiprexin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Dicloridrato de pramipexol | Livipark | Minergi | Mirapex | Pisa | Pramipezan | Quera | Quera lp | Rocky | Rocky lp | Sifrol | Stabil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pramipexol er sandoz | Pramipexol er zentiva | Pramipexol helvepharm | Pramipexol mepha | Pramipexol mepha er | Pramipexol mylan | Pramipexol orion | Pramipexol sandoz | Pramipexol Spirig | Pramipexol teva | Pramipexol zentiva | Sifrol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Biopsol | Intaxel | Intaxel er | Muvend | Parmital | Sifrol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Sifrol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Mipexobex | Mirapex | Parmital | Pramipex | Pramipexol | Pramixole er | Praxol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Calmolan | Glepark | Medopexol | Mirapexin | Oprymea | Pramigen | Pramipexol +pharma | Pramipexol mylan | Pramipexol orion | Pramipexol stada | Pramipexole teva | Sifrol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Glepark | Mirapexin | Mirapexin e M | Oprymea | Pramip | Pramipexgamma | Pramipexol 1a pharma | Pramipexol Aaa | Pramipexol abz | Pramipexol accord | Pramipexol acis | Pramipexol actavis | Pramipexol al | Pramipexol Aurobindo | Pramipexol Axcount | Pramipexol basics | Pramipexol beta | Pramipexol biomo | Pramipexol bluefish | Pramipexol ct | Pramipexol dura | Pramipexol hennig | Pramipexol heumann | Pramipexol hexal | Pramipexol hormosan | Pramipexol mylan | Pramipexol neuraxpharm | Pramipexol puren | Pramipexol q | Pramipexol ratiopharm | Pramipexol sandoz | Pramipexol sigapharm | Pramipexol stada | Pramipexol tad | Pramipexol teva | Pramipexol winthrop | Pramipexole teva | Sifrol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alegot | Labrixile | Nulipar | Nulipar lp | Parmital | Pexole | Sifrol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Biopsol | Labrixile | Mirapex | Nulipar | Nulipar lp</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ezaprev | Mirapexin | Oprymea | Pramipexol orion | Pramipexole portfarma | Pramipexole teva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Kinsoram | Ramixole | Sifrol | Sobopexole</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mirapexin | Oprymea | Pramimylan | Pramipexol actavis | Pramipexol Alter | Pramipexol apotex | Pramipexol aristo | Pramipexol Aurobindo | Pramipexol bluefish | Pramipexol Cinfa | Pramipexol Combix | Pramipexol kern pharma | Pramipexol mabo | Pramipexol mylan | Pramipexol Normon | Pramipexol Pensa | Pramipexol Qualigen | Pramipexol ratiopharm | Pramipexol sandoz | Pramipexol stada | Pramipexol tarbis | Pramipexol Teva | Pramipexol vegal | Tarocne</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Derinik | Glepark | Oprymea | Pramigen | Pramipexol sandoz | Pramipexol stada | Pramipexole accord | Pramipexole bluefish | Pramipexole orion | Pramipexole teva | Sifrol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Oprymea | Pramipexole accord | Pramipexole actavis | Pramipexole arrow | Pramipexole biogaran | Pramipexole bluefish | Pramipexole eg | Pramipexole mylan | Pramipexole qualimed | Pramipexole Ranbaxy | Pramipexole sandoz | Pramipexole teva | Pramipexole Winthrop | Pramipexole zentiva lp | Pramipexole zydus | Sifrol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mirapexin | Neliprax | Oprymea | Pipexus | Pramipexole | Pramipexole arrow | Pramipexole zentiva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Glepark | Mariprax | Medopexol | Miraleton | Miraparkin | Mirapexin | Mirapezol | Nervius | Oprymea | Parxamil | Pramifer | Pramipexole mylan | Pramipexole/Teva | Pramixol | Primizol | Rapexole | X tremble</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo pramipexole | Mirapex | Pms pramipexole</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Mirapexin | Oprymea | Pramipeksol PharmaS | Pramipeksol Pliva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Calmolan | Erimexol | Mirapexin | Oprymea | Pramipexole Bluefish | Pramipexole Glenmark | Pramipexole orion | Pramipexole teva | Pramitenorm</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Pramipexole | Pramivex | Sifrol | Treatson</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Miramel | Mirapexin | Oprymea | Pramipexole | Pramipexole Bluefish | Prapexin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Sifrol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Mirapex | Movexol | Parpex | Prami | Pramiday | Pramipar | Pramipex | Pramirol | Pramiset | Pramitrem | Prexol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mirapexin | Oprymea | Pramiperal | Pramipexolo Accord | Pramipexolo angenerico | Pramipexolo aurobindo | Pramipexolo Bluefish | Pramipexolo doc | Pramipexolo EG | Pramipexolo Germed | Pramipexolo mylan generics | Pramipexolo Mylan Pharma | Pramipexolo Pensa | Pramipexolo Sandoz | Pramipexolo Teva | Pramipexolo teva italia | Ramixole | Senefor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Parkinzo | Parkinzo ER | Sifrol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bi sifrol | Mirapex LA | Pramipexole HCL | Pramipexole hydrochloride | Pramipexole hydrochloride ffp | Pramipexole hydrochloride sn</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Pexola | Pramipex | Ramipex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mirap | Mirapex | Parkinpexole | Pd Pexol | Pramipexole | Prapexole | Prapexole er</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Sifrol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Sifrol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ezaprev | Glepark | Medopexol | Mirapexin | Oprymea | Pramipexol Portfarma | Pramipexol torrent | Pramipexole orion | Pramipexole sandoz | Pramipexole teva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Mirapexin | Pramipexole eg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ezaprev | Medopexol | Mirapexin | Oprymea | Pramipexol Genericon | Pramipexol hennig | Pramipexole orion | Pramipexole portfarma | Sifrol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Sifrol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bogaprem | Bronid | Cartulix | Dramixol | Mepimer | Muvepexol | Parkpex | Pefhimal | Periamid | Phefimal | Pramipexol | Prekin | Sifrol | Sunam | Yiaprez</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Sifrol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Glepark | Mirapexin | Oprymea | Pramipexol | Pramipexol apotex | Pramipexol cf | Pramipexol mylan | Pramipexol sandoz | Pramipexol teva | Pramipexole accord | Sifrol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Oprymea | Pramipexol bluefish | Pramipexol orion | Pramipexol sandoz | Pramipexole teva | Sifrol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Pramipexole dr reddys | Pramipexole hydrochloride | Ramipex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Labrixile | Parmital | Pramix | Pramizol | Sifrol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Pexole | Ramipex | Sifrol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Hitoff | Mirapexin | Oprymea | Pexopar | Pramipexol stada | Pramipexole orion</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mirapex | Pramipexole | Pramipexole dihcl | Pramipexole dihydrochloride extended release</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Oprymea | Pramipexol Aurobindo | Pramipexol azevedos | Pramipexol Wynn</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Angix | Labrixile | Mipexol | Parkimeg | Parmital | Pramipexol dallas | Pramipexol dutriec | Pramipexol heisecke | Pramipexol pasteur | Pramipexol prosalud | Sifrol | Xiul</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Sifrol | Sifrol ER</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Calmolan | Glepark | Oprymea | Pramipexol stada | Pramipexol teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Mipexole | Mirapex | Oprimea | Oprimeya | Pramipexol teva | Pramipexole</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo pramipexole | Pms pramipexole | Sifrol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Derinik | Mirapexin | Oprymea | Pramipexol Aurobindo | Pramipexol sandoz | Pramipexol stada | Pramipexol teva | Pramipexol zentiva | Pramipexole accord | Pramipexole bluefish | Pramipexole ebb | Pramipexole orion | Pramipexole teva | Sifrol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Sifrol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Mirapexin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Glepark | Medopexol | Mirapexin | Oprymea | Pramigen | Pramipexol +pharma | Pramipexol orion | Pramipexol stada | Pramipexole accord | Pramipexole sandoz | Pramipexole teva | Sifrol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Pramexol | Sifrol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Sifrol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Pacto | Parkipex | Parkipex ER | Parkyn | Pexa xr | Pexola | Pranow | Ramipex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo pramipexole | Mirapex | Pexo | Pramipexole dihydrochlrodie</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Mirapex | Miraxol | Pramipeksol ic | Pramipex | Pramipexol | Pramipexol orion | Pyritan | Ramipex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Labrixile | Pexola | Pralexan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amixol | Biopsol | Labrixile | Mipax | Mirapex | Parmital</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mylan pramipexole | Oxpola | Pazoram | Pexasp | Pexola | Pramex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19170199">
<a name="19170199"></a>Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. <i>Mov Disord</i>. 2009;24(1):129-133. doi:10.1002/mds.22385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/19170199/pubmed" id="19170199" target="_blank">19170199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17706566">
<a name="17706566"></a>Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. <i>Lancet Neurol</i>. 2007;6(9):826-829. doi:10.1016/S1474-4422(07)70218-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/17706566/pubmed" id="17706566" target="_blank">17706566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851801">
<a name="22851801"></a>Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. <i>Sleep</i>. 2012;35(8):1039-1062. doi:10.5665/sleep.1988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22851801/pubmed" id="22851801" target="_blank">22851801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31700703">
<a name="31700703"></a>Barone P, Antonini A, Stanzione P, Annoni K, Asgharnejad M, Bonuccelli U. Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study. <i>J Drug Assess</i>. 2019;8(1):159-166. doi:10.1080/21556660.2019.1675670<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/31700703/pubmed" id="31700703" target="_blank">31700703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23688703">
<a name="23688703"></a>Benbir G, Ertan S, Ozekmekci S. Successful pregnancy and delivery in a patient with Parkinson's disease under pramipexole treatment. <i>Presse Med</i>. 2014;43(1):83-85. doi:10.1016/j.lpm.2013.01.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/23688703/pubmed" id="23688703" target="_blank">23688703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10223406">
<a name="10223406"></a>Bennett JP Jr, Piercey MF. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease. <i>J Neurol Sci</i>. 1999;163(1):25-31. doi:10.1016/s0022-510x(98)00307-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/10223406/pubmed" id="10223406" target="_blank">10223406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19339647">
<a name="19339647"></a>Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. <i>Mayo Clin Proc</i>. 2009;84(4):310-316. doi: 10.1016/S0025-6196(11)60538-7. PMID: 19339647; PMCID: PMC2665974.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/19339647/pubmed" id="19339647" target="_blank">19339647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9578193">
<a name="9578193"></a>Brefel C, Thalamas C, Rayet S, et al. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. <i>Br J Clin Pharmacol</i>. 1998;45(4):412-415. doi:10.1046/j.1365-2125.1998.t01-1-00704.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/9578193/pubmed" id="9578193" target="_blank">9578193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28547577">
<a name="28547577"></a>Cardon-Dunbar A, Robertson T, Roberts MS, Isbister GK. Pramipexole overdose associated with visual hallucinations, agitation and myoclonus. <i>J Med Toxicol</i>. 2017;13(4):343-346. doi:10.1007/s13181-017-0615-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/28547577/pubmed" id="28547577" target="_blank">28547577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30713891">
<a name="30713891"></a>Chaudhuri KR, Todorova A, Nirenberg MJ, et al. A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson's disease. <i>Mov Disord Clin Pract</i>. 2015;2(2):170-174. doi:10.1002/mdc3.12141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/30713891/pubmed" id="30713891" target="_blank">30713891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18688211">
<a name="18688211"></a>Chernoloz O, El Mansari M, Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. <i>Neuropsychopharmacology</i>. 2009;34(3):651-661. doi:10.1038/npp.2008.114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/18688211/pubmed" id="18688211" target="_blank">18688211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728740">
<a name="18728740"></a>Constantinescu R. Update on the use of pramipexole in the treatment of Parkinson's disease. <i>Neuropsychiatr Dis Treat</i>. 2008;4(2):337-352. doi:10.2147/ndt.s2325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/18728740/pubmed" id="18728740" target="_blank">18728740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30363519">
<a name="30363519"></a>Crispo JAG, Willis AW, Thibault DP, et al. Associations between cardiovascular events and nonergot dopamine agonists in Parkinson's disease. <i>Mov Disord Clin Pract</i>. 2015;3(3):257-267. doi: 10.1002/mdc3.12286<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/30363519/pubmed" id="30363519" target="_blank">30363519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31456212">
<a name="31456212"></a>Cutsforth-Gregory JK, Low PA. Neurogenic orthostatic hypotension in Parkinson disease: a primer. <i>Neurol Ther</i>. 2019;8(2):307-324. doi:10.1007/s40120-019-00152-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/31456212/pubmed" id="31456212" target="_blank">31456212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24078717">
<a name="24078717"></a>Demartini B, Ricciardi L, Ward A, Edwards MJ. Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma. <i>J Neurol Neurosurg Psychiatry</i>. 2014;85(4):471. doi:10.1136/jnnp-2013-306043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/24078717/pubmed" id="24078717" target="_blank">24078717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23083216">
<a name="23083216"></a>Dostal M, Weber-Schoendorfer C, Sobesky J, Schaefer C. Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series. <i>Eur J Neurol</i>. 2013;20(9):1241-1246. doi:10.1111/ene.12001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/23083216/pubmed" id="23083216" target="_blank">23083216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19515253">
<a name="19515253"></a>Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. <i>BMC Neurol</i>. 2009;9:23. doi:10.1186/1471-2377-9-23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/19515253/pubmed" id="19515253" target="_blank">19515253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22993451">
<a name="22993451"></a>Edwards MJ. Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine 'switch'. <i>J Neurol Neurosurg Psychiatry</i>. 2013;84(2):120. doi:10.1136/jnnp-2012-303570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22993451/pubmed" id="22993451" target="_blank">22993451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12688834">
<a name="12688834"></a>Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. <i>Drug Saf</i>. 2003;26(6):439-444. doi:10.2165/00002018-200326060-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/12688834/pubmed" id="12688834" target="_blank">12688834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24587918">
<a name="24587918"></a>Farha KA, Baljé-Volkers C, Tamminga W, den Daas I, van Os S. Dopamine D2R agonist-induced cardiovascular effects in healthy male subjects: potential implications in clinical settings. <i>ISRN Neurol</i>. 2014;2014:956353. doi:10.1155/2014/956353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/24587918/pubmed" id="24587918" target="_blank">24587918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26844792">
<a name="26844792"></a>Fawcett J, Rush AJ, Vukelich J, et al. Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression. <i>Am J Psychiatry</i>. 2016;173(2):107-111. doi:10.1176/appi.ajp.2015.15060788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/26844792/pubmed" id="26844792" target="_blank">26844792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2012">
<a name="FDA.2012"></a>Food and Drug Administration (FDA) Drug Safety Communication. Ongoing safety review of Parkinson's drug Mirapex (pramipexole) and possible risk of heart failure. <a href="http://www.fda.gov/Drugs/DrugSafety/ucm319779.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm319779.htm</a>. Published 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10371546">
<a name="10371546"></a>Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. <i>Neurology</i>. 1999;52(9):1908-1910. doi:10.1212/wnl.52.9.1908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/10371546/pubmed" id="10371546" target="_blank">10371546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24614668">
<a name="24614668"></a>Galati S, Möller JC, Städler C. Ropinirole-induced Pisa syndrome in Parkinson disease. <i>Clin Neuropharmacol</i>. 2014;37(2):58-59. doi:10.1097/WNF.0000000000000022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/24614668/pubmed" id="24614668" target="_blank">24614668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22937989">
<a name="22937989"></a>García-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. <i>Eur J Neurol</i>. 2012;19(11):1385-1396. doi:10.1111/j.1468-1331.2012.03853.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22937989/pubmed" id="22937989" target="_blank">22937989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448465">
<a name="27448465"></a>Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation. <i>Sleep Med</i>. 2016;21:1-11. doi:10.1016/j.sleep.2016.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/27448465/pubmed" id="27448465" target="_blank">27448465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28818004">
<a name="28818004"></a>Geyer J, Bogan R. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations. <i>Postgrad Med</i>. 2017;129(7):667-675. doi:10.1080/00325481.2017.1360747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/28818004/pubmed" id="28818004" target="_blank">28818004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33880737">
<a name="33880737"></a>Gossard TR, Trotti LM, Videnovic A, St Louis EK. Restless legs syndrome: contemporary diagnosis and treatment. <i>Neurotherapeutics</i>. 2021;18(1):140-155. doi:10.1007/s13311-021-01019-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/33880737/pubmed" id="33880737" target="_blank">33880737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861870">
<a name="28861870"></a>Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine agonists and impulse control disorders: a complex association. <i>Drug Saf</i>. 2018;41(1):19-75. doi:10.1007/s40264-017-0590-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/28861870/pubmed" id="28861870" target="_blank">28861870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22500116">
<a name="22500116"></a>Hametner EM, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. <i>Clin Interv Aging</i>. 2012;7:83-88. doi:10.2147/CIA.S11829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22500116/pubmed" id="22500116" target="_blank">22500116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31008016">
<a name="31008016"></a>Hanset N, Hantson P, Saint-Marcoux F, Devresse A, Jadoul M, Labriola L. Influence of hemodialysis on pramipexole pharmacokinetics: lessons from two cases and literature review. <i>Clin Nephrol Case Stud</i>. 2019;7:11-16. doi:10.5414/CNCS109641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/31008016/pubmed" id="31008016" target="_blank">31008016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11798367">
<a name="11798367"></a>Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. <i>JAMA</i>. 2002;287(4):455-463. doi: 10.100/jama.287.4.455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/11798367/pubmed" id="11798367" target="_blank">11798367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23881697">
<a name="23881697"></a>Hsieh PH, Hsiao FY. Risk of heart failure associated with dopamine agonists: a nested case-control study. <i>Drugs Aging</i>. 2013;30(9):739-745. doi:10.1007/s40266-013-0102-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/23881697/pubmed" id="23881697" target="_blank">23881697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22353251">
<a name="22353251"></a>Kim HJ, Jeon BS, Kim SH, Han SH. Reversible antecollis associated with pramipexole in a patient with Parkinson's disease. <i>J Clin Neurosci</i>. 2012;19(6):903-904. doi:10.1016/j.jocn.2011.09.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22353251/pubmed" id="22353251" target="_blank">22353251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20484726">
<a name="20484726"></a>Kolla BP, Mansukhani MP, Barraza R, Bostwick JM. Impact of dopamine agonists on compulsive behaviors: a case series of pramipexole-induced pathological gambling. <i>Psychosomatics</i>. 2010;51(3):271-273. doi:10.1176/appi.psy.51.3.271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/20484726/pubmed" id="20484726" target="_blank">20484726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11030798">
<a name="11030798"></a>Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. <i>Arch Neurol</i>. 2000;57(10):1461-1463. doi:10.1001/archneur.57.10.1461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/11030798/pubmed" id="11030798" target="_blank">11030798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29383607">
<a name="29383607"></a>Kurin M, Bielefeldt K, Levinthal DJ. Prevalence of nausea and vomiting in adults using ropinirole: a systematic review and meta-analysis. <i>Dig Dis Sci</i>. 2018;63(3):687-693. doi:10.1007/s10620-018-4937-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/29383607/pubmed" id="29383607" target="_blank">29383607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24182521">
<a name="24182521"></a>Lamichhane D, Narayanan NS, Gonzalez-Alegre P. Two cases of pregnancy in Parkinson's disease. <i>Parkinsonism Relat Disord</i>. 2014;20(2):239-240. doi:10.1016/j.parkreldis.2013.10.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/24182521/pubmed" id="24182521" target="_blank">24182521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18412854">
<a name="18412854"></a>Li CT, Tsai SJ, Hwang JP. Pramipexole-induced psychosis in Parkinson's disease. <i>Psychiatry Clin Neurosci</i>. 2008;62(2):245. doi:10.1111/j.1440-1819.2008.01766.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/18412854/pubmed" id="18412854" target="_blank">18412854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26765466">
<a name="26765466"></a>Liu GJ, Wu L, Wang SL, et al. Incidence of augmentation in primary restless legs syndrome patients may not be that high: evidence from a systematic review and meta-analysis. <i>Medicine (Baltimore)</i>. 2016;95(2):e2504. doi:10.1097/MD.0000000000002504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/26765466/pubmed" id="26765466" target="_blank">26765466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7664822">
<a name="7664822"></a>Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. <i>Eur J Pharmacol</i>. 1995;290(1):29-36. doi:10.1016/0922-4106(95)90013-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/7664822/pubmed" id="7664822" target="_blank">7664822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15007148">
<a name="15007148"></a>Miranda M, Kagi M, Fabres L, et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. <i>Neurology</i>. 2004;62(5):831-832. doi:10.1212/01.wnl.0000113752.14744.15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/15007148/pubmed" id="15007148" target="_blank">15007148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mirapex.1">
<a name="Mirapex.1"></a>Mirapex (pramipexole dihydrochloride) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mirapex.2">
<a name="Mirapex.2"></a>Mirapex (pramipexole dihydrochloride) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd: March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mirapex.3">
<a name="Mirapex.3"></a>Mirapex ER (pramipexole dihydrochloride) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22123498">
<a name="22123498"></a>Mokhles MM, Trifirò G, Dieleman JP, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. <i>Pharmacol Res</i>. 2012;65(3):358-364. doi:10.1016/j.phrs.2011.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22123498/pubmed" id="22123498" target="_blank">22123498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15372610">
<a name="15372610"></a>Mucchiut M, Belgrado E, Cutuli D, Antonini A, Bergonzi P. Pramipexole-treated Parkinson's disease during pregnancy. <i>Mov Disord</i>. 2004;19(9):1114-1115. doi:10.1002/mds.20148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/15372610/pubmed" id="15372610" target="_blank">15372610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16987735">
<a name="16987735"></a>Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. <i>Lancet Neurol</i>. 2006;5(10):878-886. doi:10.1016/S1474-4422(06)70576-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/16987735/pubmed" id="16987735" target="_blank">16987735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16513886">
<a name="16513886"></a>Perea E, Robbins BV, Hutto B. Psychosis related to ropinirole. <i>Am J Psychiatry</i>. 2006;163(3):547-548. doi:10.1176/appi.ajp.163.3.547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/16513886/pubmed" id="16513886" target="_blank">16513886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8891576">
<a name="8891576"></a>Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. <i>Eur J Pharmacol</i>. 1996;312(1):35-44. doi:10.1016/0014-2999(96)00454-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/8891576/pubmed" id="8891576" target="_blank">8891576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20065130">
<a name="20065130"></a>Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. <i>Arch Neurol</i>. 2010;67(1):58-63. doi:10.1001/archneurol.2009.294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/20065130/pubmed" id="20065130" target="_blank">20065130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22109939">
<a name="22109939"></a>Renoux C, Dell'Aniello S, Brophy JM, Suissa S. Dopamine agonist use and the risk of heart failure. <i>Pharmacoepidemiol Drug Saf</i>. 2012;21(1):34-41. doi:10.1002/pds.2267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22109939/pubmed" id="22109939" target="_blank">22109939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26106453">
<a name="26106453"></a>Rosenstein A, Rabin M, Kurlan R. Augmentation in restless legs syndrome: treatment with gradual medication modification. <i>Open Neurol J</i>. 2015;9:4-6. doi:10.2174/1874205X01509010004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/26106453/pubmed" id="26106453" target="_blank">26106453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17578485">
<a name="17578485"></a>Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2007;64(5):591-602. doi:10.1111/j.1365-2125.2007.02938.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/17578485/pubmed" id="17578485" target="_blank">17578485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30142750">
<a name="30142750"></a>Shen Z, Kong D. Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease. <i>Medicine (Baltimore)</i>. 2018;97(34):e11316. doi:10.1097/MD.0000000000011316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/30142750/pubmed" id="30142750" target="_blank">30142750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Silber.2021">
<a name="Silber.2021"></a>Silber MH. Treatment of restless legs syndrome and periodic limb movement disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spindler.2021">
<a name="Spindler.2021"></a>Spindler MA. Initial pharmacologic treatment of Parkinson disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29858440">
<a name="29858440"></a>Tashkent Y, Aiyappan V. Lesson of the month 2: An unusual adverse reaction associated with pramipexole. <i>Clin Med (Lond)</i>. 2018;18(3):259-260. doi:10.7861/clinmedicine.18-3-259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/29858440/pubmed" id="29858440" target="_blank">29858440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16130408">
<a name="16130408"></a>Tomita M, Otsuka Y, Iida R, Kobayashi S, Kuriyama S, Hosoya T. Syndrome of inappropriate ADH secretion (SIADH) induced by pramipexole in a patient with Parkinson's disease. Article in Japanese. <i>Nihon Jinzo Gakkai Shi</i>. 2005;47(5):531-535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/16130408/pubmed" id="16130408" target="_blank">16130408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29926223">
<a name="29926223"></a>Tüfekçioğlu Z, Hanağası H, Yalçın Çakmaklı G, et al. Use of anti-Parkinson medication during pregnancy: a case series. <i>J Neurol</i>. 2018;265(8):1922-1929. doi:10.1007/s00415-018-8937-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/29926223/pubmed" id="29926223" target="_blank">29926223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14725821">
<a name="14725821"></a>Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). <i>Sleep Med</i>. 2004;5(1):9-14. doi:10.1016/j.sleep.2003.07.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/14725821/pubmed" id="14725821" target="_blank">14725821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30363881">
<a name="30363881"></a>Yeung EYH, Cavanna AE. Sleep attacks in patients with Parkinson's disease on dopaminergic medications: a systematic review. <i>Mov Disord Clin Pract</i>. 2014;1(4):307-316. doi: 10.1002/mdc3.12063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/30363881/pubmed" id="30363881" target="_blank">30363881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28104232">
<a name="28104232"></a>Yu XX, Fernandez HH. Dopamine agonist withdrawal syndrome: A comprehensive review. <i>J Neurol Sci</i>. 2017;374:53-55. doi:10.1016/j.jns.2016.12.070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/28104232/pubmed" id="28104232" target="_blank">28104232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30591018">
<a name="30591018"></a>Zhang P, Li Y, Nie K, Wang L, Zhang Y. Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review. <i>BMC Neurol</i>. 2018;18(1):221. doi:10.1186/s12883-018-1230-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/30591018/pubmed" id="30591018" target="_blank">30591018</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9560 Version 466.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
